Global Qualitative Platelet Disorders Treatment Market Highlights Over 2022 - 2030
The global qualitative platelet disorders treatment market is estimated to garner a notable revenue by growing at a robust CAGR over the forecast period, i.e., 2022 – 2030. Qualitative platelet disorder (QPD), also known as, Glanzmann thrombasthenia, is an autosomal recessive genetic disorder, in which platelets are unable to form proper clots due to the poor quality of platelets. The growth of the market can be attributed to the growing incidences of QPD across the globe. According to the National Organization of Rare Diseases (NORD), approximately 500 cases of QPD are reported every year, however, more than half of the cases go unreported. The symptoms of this disorder are noticeable from birth or very early in life, and leading a normal life is impossible for the patient. This is why, the demand for a permanent cure is surging across the globe, which is estimated to further boost the market growth. Moreover, the growing investment in the research and development activities in the healthcare sector is estimated to boost the market growth.
The market is segmented by treatment into platelet transfusion, hormonal therapy, anti-fibrinolytic medications, genetic counselling, and others, out of which, the genetic counselling segment is anticipated to hold the largest share in the global qualitative platelet disorders treatment market as this is the only method to avoid QPD transmission through generations. As there is no permanent cure for this, prevention of the disorder is the best possible solution, and government agencies across the world are trying to spread awareness regarding the prevention of QPD. CLICK TO DOWNLOAD SAMPLE REPORT
Major Macro-Economic Indicators Impacting the Market Growth
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
Global Qualitative Platelet Disorders Treatment Market Regional Synopsis
Regionally, the global qualitative platelet disorders treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in Middle East & Africa region is estimated to witness noteworthy growth over the forecast period owing to the higher prevalence of qualitative platelet disorder. QPD is a genetic disease, which is why, it is more common in communities that practice intermarriage. This is estimated to boost the growth of the regional market.
The market in the North America region is anticipated to gain the largest market share throughout the forecast period on account of high healthcare expenditure, and presence of major pharmaceutical companies in the region manufacturing the drugs to treat QPD. According to the statistics by the World Bank, in 2018, North America spent USD 10,050.516 for the healthcare of every individual.
The global qualitative platelet disorders treatment market is further classified on the basis of region as follows:
Our in-depth analysis of the global qualitative platelet disorders treatment market includes the following segments:
Top Featured Companies Dominating the Market
FREQUENTLY ASKED QUESTIONS
Growing cases of QPD and other genetic diseases is estimated to boost the market growth.
The market is anticipated to attain a robust CAGR over the forecast period, i.e., 2022-2030.
The major players in the market are Merck & Co., Inc., Siemens Healthcare GmbH, Boehringer Ingelheim International GmbH, Johnson & Johnson Services, Inc., and others.
The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by treatment, end-user, and by region.
The genetic counselling segment is anticipated to hold largest market size over the forecast period and display significant growth opportunities.
High cost of treatment is estimated to hamper the market growth.
The market in the North America region is estimated to provide more business opportunities over the forecast period on account of presence of major pharmaceutical companies in the region.
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization